Document Detail

Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
MedLine Citation:
PMID:  15477639     Owner:  NLM     Status:  MEDLINE    
Oxaliplatin (Eloxatin; Sanofi-Synthelabo Inc.; New York, NY) is a third-generation platinum agent indicated for the treatment of colorectal cancer. Severe hypersensitivity reactions to oxaliplatin rarely occur; however, they do represent a threat to the small number of patients that are occasionally affected. We developed a desensitization protocol and successfully applied it to a patient with severe, grade 3, hypersensitivity to oxaliplatin. For patients who have mild sensitivity to oxaliplatin, slowing the run rate down and giving an antihistamine and/or a steroid usually suffice. Desensitization will help to provide the small number of patients who experience severe hypersensitivity reactions with the ability to further receive an effective therapy for their colorectal cancer. The desensitization protocol is described in detail.
David Gammon; Pankaj Bhargava; Michael J McCormick
Related Documents :
11379299 - Chronotherapy of colorectal cancer metastases.
15341879 - Management of adverse events and other practical considerations in patients receiving c...
20526099 - Optimal delivery of cytotoxic chemotherapy for colon cancer.
9435929 - Efficacy and safety of docetaxel in clinical trials.
12633839 - An overview of current results with the gemcitabine and docetaxel combination as initia...
19610679 - Budget impact analysis of ixabepilone used according to fda approved labeling in treatm...
19321899 - Chemopreventive role of fruits and vegetables in oropharyngeal cancer.
11549559 - Cancer mortality among workers exposed to amphibole-free chrysotile asbestos.
22036019 - Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer:...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The oncologist     Volume:  9     ISSN:  1083-7159     ISO Abbreviation:  Oncologist     Publication Date:  2004  
Date Detail:
Created Date:  2004-10-12     Completed Date:  2005-01-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  546-9     Citation Subset:  IM    
UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, Massachusetts 01655, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  adverse effects*,  immunology*
Colorectal Neoplasms / drug therapy
Desensitization, Immunologic / methods*
Dose-Response Relationship, Drug
Drug Hypersensitivity / prevention & control*
Infusions, Intravenous
Middle Aged
Organoplatinum Compounds / administration & dosage,  adverse effects*,  immunology*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Organoplatinum Compounds; 63121-00-6/oxaliplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Practical aspects of weekly docetaxel administration schedules.
Next Document:  Superior sulcus tumors: a mini-review.